HONG KONG, March 24, 2026 /PRNewswire/ — The global automotive industry is undergoing rapid transformation. At GAC, technological innovation remains at the core of our mission to deliver safer, more efficient, and more reliable mobility experiences for users worldwide. With proprietary core technologies, GAC is accelerating its global footprint and earning trust through quality—trust built on an unwavering commitment to high standards, high requirements, and high quality.

High safety standards are fundamental to our approach. The Magazine Battery represents comprehensive innovation from cell to system. During R&D, GAC subjected the technology to tests far exceeding industry norms and proactively meeting future national standards. Under extreme conditions such as needle penetration, crushing, and twisting, the Magazine Battery does not ignite or explode, mitigating risks at the source. It is this commitment to high standards that transforms technology into a solid foundation of user trust.

GAC applies high requirements throughout the entire vehicle usage cycle. The “GAC X-SOUL Safety Protection System” extends safety across the full lifecycle, enabling early risk identification, intelligent stability control for hazard avoidance—all rigorously validated to standards far exceeding industry benchmarks, from 24/7 monitoring to dual-redundancy backups for key systems. With risks “rehearsed” in advance, round-the-clock protection ensures peace of mind on every journey.

Technological innovation delivers high-quality outcomes. The Quark Electric Drive 2.0, named one of the “World’s Top 10 Electric Drive Systems,” features lightweight construction and high efficiency, delivering powerful performance while reducing energy consumption and enhancing range and responsiveness. The third-generation hybrid technology, also recognized among the “World’s Top 10 Hybrid Systems,” achieves an optimal balance between power and fuel economy through high integration, offering a quiet, smooth, and premium driving experience. These are high-quality breakthroughs in efficiency, performance, and reliability.

From battery safety to intelligent protection, from electric drive efficiency to hybrid driving experience, GAC is redefining the quality benchmark for new energy vehicles with a portfolio of internationally recognized core technologies. As we expand into global markets, GAC will continue to uphold high standards, high requirements, and high quality—bringing China’s innovation power and craftsmanship to more users around the world.

For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social.

• Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase.
• R&D Expenses was approximately RMB1319.68 million.
• Loss for the period was RMB381.97 million, adjusted annual loss^[1] was approximately RMB211.28 million.
• Cash and financial assets^[2] amounted to approximately RMB4559.36 million, with ample cash reserves.
• The debt-to-asset ratio^[3] further declined to 18.7%.

CHENGDU, China, March 24, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company“, Stock Code: 6990.HK) announced its audited consolidated results for the year ended 31 December 2025 (the “Reporting Period“).

Kelun-Biotech is leveraging its core strengths and proprietary OptiDC™ technology platform to continue deepening its presence in the ADC and novel DC drug field. The company is actively advancing cutting-edge modalities including bispecific ADCs, RDCs, iADCs, and DACs, building a differentiated pipeline with strong global competitiveness. At the same time, Kelun-Biotech is steadily advancing product commercialization, achieving transformational growth across its business. To date, the company has four products with eight indications approved for marketing in China, including Sacituzumab Tirumotecan (佳泰莱^®), Trastuzumab Botidotin (舒泰莱^®), Tagitanlimab (科泰莱^®), and Cetuximab N01 (达泰莱^®). Among them, three products with five indications have been included in the 2025 National Reimbursement Drug List (NRDL), establishing a fully integrated drug development ecosystem that spans R&D through commercialization.

As of now, the company has built a robust pipeline of more than 30 drug candidates, with over 10 in the clinical stage, and are gradually expanding into broader non-oncology therapeutic areas such as autoimmune diseases and metabolic disorders. Looking ahead, the company will leverage its innovative and differentiated pipeline to deliver high-quality therapeutic solutions for major unmet medical needs worldwide.

Core ADC Products’ Commercialization Realized to Solidify Long-term Performance Foundation 

Sac-TMT (sacituzumab tirumotecan, TROP2 ADC) (also known as SKB264/MK-2870) (佳泰莱^®)

TNBC:

• The Company received marketing authorization in China from the NMPA for sac-TMT in adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting).
• The Company has initiated a Phase 3 registrational study of sac-TMT monotherapy versus ICC for 1L advanced TNBC.

HR+/HER2- BC:

• In February 2026, a new indication application for sac-TMT for the treatment of adult patients with HR+/HER2- BC who have received prior endocrine therapy (ET) and at least one line of chemotherapy in advanced setting has been approved for marketing by the NMPA.
• A Phase 3 registrational study of sac-TMT versus ICC for treatment of patients with HR+/HER2- BC who received prior ET is in progress.

EGFR-mutant NSCLC:

• In March 2025, the Company received marketing authorization in China from the NMPA for sac-TMT for the treatment of adult patients with EGFR mutant-positive NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. This is the first TROP2 ADC drug approved for marketing in LC globally.
• In October 2025, the company received marketing authorization in China from the NMPA for sac-TMT for the treatment of adult patients with EGFR mutant-positive NSCLC who progressed after treatment with EGFR-TKI therapy. This is the first ADC globally to show an OS benefit compared with platinum doublet chemotherapy and be approved for advanced NSCLC following progression on only TKI therapy (2L).
• The Phase 3 registrational study of sac-TMT combined with osimertinib as first-line treatment of EGFR-mutant NSCLC and a Phase 2 study of sac-TMT monotherapy or in combination with osimertinib as neoadjuvant therapy for EGFR-mutant NSCLC are in progress.

EGFR-wild type NSCLC:

• The Phase 3 registrational study of sac-TMT in combination with KEYTRUDA®^[1] (pembrolizumab) versus pembrolizumab as first-line treatment of PD-L1 positive NSCLC met its primary endpoint. This is the first Phase 3 clinical trial of ADC combined with immune checkpoint inhibitor to achieve its primary endpoint in the first-line treatment of NSCLC.
• In January 2026, sac-TMT in combination with pembrolizumab for the first-line treatment of PD-L1 positive NSCLC were granted Breakthrough Therapy Designation by the NMPA.
• The Phase 3 registrational study of sac-TMT in combination with pembrolizumab as first-line treatment of PD-L1 negative NSCLC is in progress.

Other indications: The company is actively exploring the potential of sac-TMT both as a monotherapy and in combination with other therapies for treating other solid tumors, including GC, EC, CC, OC, UC, CRPC, HNSCC, and TC, etc.

Trastuzumab botidotin (HER2 ADC, also known as A166, 舒泰莱^®)

• In October 2025, trastuzumab botidotin was approved for marketing by the NMPA for adult patients with HER2+ BC who have received one or more prior anti-HER2 therapy. This is the first domestically developed HER2 ADC approved for 2L+ HER2+ BC in China.
• An open, multicenter Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ BC that previously received a topoisomerase inhibitor ADC is in progress.

Key Clinical Data Highlighted at International Academic Conferences and in Top Journals

• Results from the Phase 3 study of sac-TMT for the treatment of 2L EGFR-mutant NSCLC were selected for LBA and presented as an oral report in the Presidential Symposium session at the 2025 ESMO Congress. Sac-TMT achieved statistically significant and clinically meaningful improvements in ORR, PFS, and OS compared to chemotherapy. The study findings were published simultaneously online at the New England Journal of Medicine and in the first issue of 2026.
• Results from the study of sac-TMT for the treatment of 3L EGFR-mutant NSCLC were presented as an oral report at the ASCO Annual Meeting and published at the British Medical Journal. The final OS analysis of this study will be selected for LBA and presented as a mini oral report at the 2026 ELCC.
• Results from the Phase 3 study of sac-TMT for the treatment of 2L+ HR+/HER2-BC were selected for LBA and presented as an oral report at the 2025 ESMO Congress.
• Results from the Phase 3 study of trastuzumab botidotin for the treatment of 2L+ HER2+ BC were selected for LBA and presented as an oral report at the 2025 ESMO Congress.

Sustained Value Release of ADCs Under Development with Tiered Advancement of Innovation Pipeline

Phase 2 clinical stage

SKB315 (CLDN18.2 ADC):

• The Phase 1b clinical trial of SKB315 is in progress, for the treatment of GC/GEJC/PDAC, etc.
• Results of a Phase 1 study of SKB315 in patients with advanced solid tumors including GC/GEJC were presented at 2025 ESMO Congress in October 2025.

SKB410/MK-3120 (Nectin-4 ADC):

• Its partner MSD has launched 4 global Phase 1/2 clinical trial of SKB410/MK-3120 in advanced solid tumor including bladder cancer, etc.

SKB571/MK-2750 (novel bsADC): The Phase 2 clinical trial in China is ongoing.

SKB518 (novel ADC with a potential FIC target): The Phase 2 clinical trials are ongoing in China.

SKB500 (novel ADC): The Phase 2 study is ongoing in China.

Phase 1 clinical stage

SKB107 (RDC)^[2]: The Phase 1 study is ongoing.

SKB535/MK-6204 (novel ADC with potential FIC target): The Phase 1 clinical trial for SKB535 is ongoing in China.

SKB445 (novel ADC with potential FIC target): The Phase 1 clinical trials for SKB445 is ongoing in China.

SKB105/CR-003 (ITGB6 ADC): In January 2026, an IND application was approved by the CDE of NMPA for the treatment of advanced solid tumor. A Phase 1/2 trial is ongoing in China.

Strategic Layout of Non-DC Assets with Focus on Combination Therapy & Indication Expansion

Drug candidates for oncology

• Tagitanlimab (PD-L1 mAb, also known as A167) (科泰莱^®): In January 2025, the Company received marketing authorization of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of NPC from NMPA. Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC.
• In May 2025, the results of a Phase 3 clinical study of tagitanlimab in combination with cisplatin and gemcitabine for the first-line treatment of NPC were presented at the ASCO Annual Meeting.

Cetuximab N01 (EGFR mAb, also known as A140) (达泰莱^®):

• In February 2025, the Company received marketing authorization in China from the NMPA for Cetuximab N01 Injection used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of RAS wild-type mCRC.

Lunbotinib Fumarate Capsules (RET inhibitor, also known as A400/EP0031)(宁泰莱^®)^[3]：

• An NDA was accepted for review by the CDE of the NMPA of China for the 1L+ treatment of RET-fusion positive NSCLC.
• The company is also conducting a Phase 1b/2 clinical study for RET+ MTC and solid tumor in China.
• Ellipses Pharma is progressing their phase 2 clinical study globally outside of China.
• In May 2025, results from the Phase 1 study of Lunbotinib Fumarate Capsules in patients with advanced RET-mutant MTC were presented at the ASCO Annual Meeting.

SKB118/CR-001 (PD-1/VEGF bsAb):

• In January 2026, Crescent Biopharma announced the regulatory clearance of the IND application for SKB118 by FDA to initiate its global ASCEND Phase 1/2 clinical trial for the treatment of advanced solid tumors, and the first patient has been dosed in February, 2026.
• The company is planning to initiate the Phase 1/2 clinical study for SKB118 in China in the first half of 2026.

Drug candidates for autoimmune diseases

SKB378/WIN378 (TSLP mAb):

• In January 2025, an IND application for SKB378 for the treatment of COPD was approved by the NMPA.
• Its collaboration partner, Windward Bio, has launched the Phase 2 POLARIS global trial in patients with asthma.

SKB575 (TSLP/undisclosed target bsAb): In March 2026, an IND application for SKB575 for the treatment of atopic dermatitis was approved by the NMPA.

Drug candidates for other non-oncology diseases

SKB336 (FXI/FXIa mAb): The company completed Phase 1 clinical trial in China.

Multiple Products First Included in National Reimbursement Drug List with Accelerated Market Coverage 

In 2025, the Company witnessed an explosive growth in the commercialization of its innovative achievements. The Company has also filed an NDA for Lunbotinib Fumarate Capsules and expects to commence its commercialization in the second half of 2026 or the first half of 2027, subject to regulatory communications and marketing approval. To date, the company’s initial commercial product portfolio, consisting of five products, has taken shape.

Supported by national innovation policies, the Company has successfully secured the first-time inclusion of three of its commercialized products, namely 佳泰莱^®, 科泰莱^® and 达泰莱^®, in the National Reimbursement Drug List (國家醫保藥品目錄), which officially took effect on January 1, 2026, and is expected to benefit more patients faster and better.

Steady Advancement of Global Collaboration and Comprehensive Strength Authoritatively Recognized

Collaboration with MSD: As at the date of this announcement, MSD is evaluating initiated 17 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer, including BC, LC, gynecological cancers, GI cancer and GU cancer. In addition to sac-TMT, the company is also collaborating with MSD on certain ADC assets to continuously explore favorable ADC pipeline portfolios.

Collaboration with Ellipses Pharma: The Company has deepened its collaboration with Ellipses Pharma on A400/EP0031, which has cleared by the FDA to progress into Phase 2 clinical development. As at December 31, 2025, a total of 39 clinical sites in the United States, Europe and UAE were set up for Lunbotinib Fumarate Capsules.

Collaboration with Windward Bio: In January 2025, the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries). Windward Bio has launched the Phase 2 POLARIS global trial in patients with asthma.

Collaboration with Crescent Biopharma. In December 2025, the company and Crescent Biopharma entered into a strategic collaboration for SKB105/CR-003 and SKB118 (a PD1 x VEGF bsAb, also known as CR-001). Under the collaboration, the company granted Crescent Biopharma exclusive rights to research, develop, manufacture and commercialize SKB105/CR-003 in the United States, Europe and all other markets outside of Greater China. In return, the compamy obtained exclusive rights from Crescent Biopharma to research, develop, manufacture and commercialize SKB118/CR-001 in Greater China.

In January 2026, Crescent Biopharma announced the regulatory clearance of the IND application for SKB118 by FDA to initiate its global ASCEND Phase 1/2 clinical trial for the treatment of advanced solid tumors, and the first patient has been dosed in February, 2026.

Continuous Improvement of ESG Capabilities to Consolidate the Foundation for Sustainable Development

Through the establishment and continuous improvement of the ESG governance structure, the Company comprehensively enhances ESG performance ability and ensures the Company’s sustainable development. In May 2025, the company was awarded “Best ESG” by Extel. In March 2026, the Company had received a rating of “AA” in the MSCI ESG Rating Assessment.

Outlook

In 2026, Kelun-Biotech will continue to drive innovation and strengthen its operational capabilities, steadily advancing towards becoming a world-class biopharmaceutical company. Specifically, the Company will implement the following development strategies: advancing differentiated pipelines targeting indications with significant medical needs; innovating on and optimizing payload-linker strategies and novel DC designs and structures, while expanding applications in non-oncology diseases; enhancing its end-to-end drug development and commercialization capabilities; expanding business landscape and strategic partnerships and improve our capabilities for the development, registration and commercialization of our products in ex-China market; and optimizing its operational systems with the aim of becoming a leading global biopharmaceutical company.

About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (referred to as “Kelun-Biotech” Stock Code: 6990.HK) is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., specializing in the R&D, manufacturing, commercialization, and global collaboration of innovative biological drugs and small molecule drugs. The Company focuses on addressing unmet clinical needs both globally and in China, with a strategic emphasis on major disease areas such as oncology, autoimmune disorders, and metabolic diseases. It is dedicated to building an international platform for drug R&D and industrialization, with the aim of becoming a global leader in the innovative drug sector. Currently, Kelun-Biotech has over 30 key innovative drug projects, including 4 projects covering 8 indications that have received market approval, 1 project at the NDA stage, and more than 10 projects in clinical trials. The Company has also successfully established its internationally renowned proprietary ADC and novel conjugated drug platform, OptiDC^TM, with 2 ADC projects covering 5 indications approved for market launch, and several ADC or novel conjugated drug projects in clinical or preclinical development.

SINGAPORE, March 24, 2026 /PRNewswire/ — Digital travel platform Agoda has revealed its recommendations of Asia’s remarkable diving destinations, where coral reefs, rare marine species, and dramatic underwater landscapes attract divers from around the world. As adventure travel continues to gain popularity, more travelers are adding scuba diving and snorkeling to their itineraries to experience Asia’s rich marine biodiversity firsthand.

From remote reefs to unique underwater formations, Asia offers diverse diving experiences for both beginners and seasoned divers. Many of these sites sit within the Coral Triangle, one of the most biodiverse marine regions on the planet.

Agoda has curated a list of standout diving destinations across Asia that offer memorable underwater encounters.

Sipadan Island, Malaysia – Sipadan Island is widely regarded as one of the world’s premier dive sites. Formed by living corals growing on top of an extinct volcanic cone, the island is surrounded by thriving marine ecosystems. Divers regularly encounter sea turtles, barracudas, and reef sharks, while dramatic wall dives descend along a steep drop-off reaching depths of around 600 meters.

Raja Ampat, Indonesia – Located in the heart of the Coral Triangle, Raja Ampat is known for its extraordinary marine biodiversity. The region is home to more than 1,500 species of fish and over 600 species of coral. Its remote location helps preserve pristine reef systems, making it one of the most sought-after destinations for both diving and snorkeling.

Similan Islands, Thailand – The Similan Islands are famous for their clear waters and striking underwater rock formations. Divers explore granite boulders, swim-through passages, and coral gardens, while encountering marine life such as manta rays and whale sharks.

Tubbataha Reefs Natural Park, Philippines – A UNESCO World Heritage Site located in the Sulu Sea, Tubbataha Reefs Natural Park is one of the Philippines’ most protected marine areas. Accessible mainly by liveaboard boats, the remote reef system offers encounters with sharks, manta rays, and large schools of pelagic fish in a pristine environment.

Komodo National Park, Indonesia – Known for its powerful currents and nutrient-rich waters, Komodo National Park offers some of Southeast Asia’s most dynamic dive sites. Drift dives reveal vibrant coral reefs and large marine species, while the surrounding islands are also home to the famous Komodo dragon.

Malapascua Island, Philippines – Malapascua Island has become globally known for its regular sightings of thresher sharks. Divers gather at Monad Shoal at dawn, where these elusive sharks visit cleaning stations. The area also offers night dives and macro photography opportunities among colorful reef habitats.

Andaman Islands, India – The Andaman Islands offer a mix of coral reefs, underwater cliffs, and historic shipwrecks. Clear waters and relatively untouched marine environments make the islands appealing for scuba diving and freediving.

Yonaguni Monument, Japan – Off the coast of Yonaguni Island lies one of the ocean’s most debated formations. The Yonaguni Monument features massive underwater stone structures that resemble terraces and steps. Whether natural or man-made, the site attracts divers intrigued by its scale and mystery.

Andrew Smith, Senior Vice President, Supply at Agoda shared, “Many travelers come to Asia for its beaches, but beneath the sea there are ecosystems that are just as remarkable. From coral reefs to rare marine encounters, these locations offer experiences that stay with travelers long after the trip ends. At Agoda, we are passionate about helping travelers discover such wonders and create unforgettable memories, with great deals across our wide range of accommodation, flights, and activities.”

For those planning their next diving getaway, Agoda offers over 6 million holiday properties, more than 130,000 flight routes, and over 300,000 activities, all of which can be combined in the same booking. Discover the best deals on Agoda’s mobile app and start planning your next underwater adventure today.

DUESSELDORF, Germany, March 24, 2026 /PRNewswire/ — RITFIT, a pioneering U.S. home fitness brand and a platform of RITFITNESS INC. dedicated to empowering individuals with high-quality and accessible equipment, officially makes its entry into the German market, one of Europe’s largest and most professional fitness markets. 

Specializing in compact, professional-grade strength equipment, RITFIT has chosen Germany as its strategic entry point for European expansion in 2026. With a highly mature fitness culture and rigorous standards, Germany offers the ideal proving ground for engineering excellence, reliability, and long-term value. In 2024, the country recorded approximately 11.7 million gym members and €5.8 billion ($6.88 billion) in industry revenue. Boasting a fitness penetration rate of 14%, which is remarkably above the European average, Germany continues to lead the continent in both membership volume and revenue growth.

RITFIT’s Germany launch will include a localized online platform, real-world training scenarios presentations, and collaborations through fitness exhibitions (FIBO), city events and local sports clubs (Sportvereine) as well as the local coaching networks, an integrated approach to establish a long-term market entry model centered on credibility rather than short-term promotional development.

German consumers take a highly rational, professional approach to fitness equipment, prioritizing durability, real-world performance, and long-term functionality over fleeting trends or flashy marketing. With average living space around 47m² per capita—significantly less than the U.S. (70m²)—space efficiency becomes a decisive factor in purchasing decisions.

For RITFIT, this compact urban environment plays directly to the brand’s core strengths: multi-functional design and space-efficient engineering. Germany’s high-barrier, quality-driven market demands rigorous evaluation of specifications, steel quality, structural integrity, and safety—precisely the kind of “engineering-first” market where RITFIT excels.

“Germany is not a trend-driven market—it is a credibility-driven one,” said Ashley, Marketing Specialist at RITFIT. “Entering Germany means entering one of Europe’s most demanding strength training environments. If our systems can earn trust here, they can earn trust anywhere. This launch isn’t about short-term expansion, but about building long-term legitimacy in a market that values engineering quality, space efficiency, and real performance.”

Additionally, there are approximately 85,000 to 90,000 registered sports clubs (Sportvereine) in Germany, with a combined membership exceeding 27 million. Roughly one in three Germans has participated in a sports club at some point in their lives, underscoring the high level of trust placed in these training institutions.

RITFIT’s strategic entry into Germany will help drive the adoption of compact, gym-capable strength training solutions across Europe, providing consumers with professional-grade equipment built to last and adapted to urban living.

“Our name is inspired by the combination of the words ‘Right’ and ‘Fitness’. RITFITwas born from a belief in both the right to control one’s fitness journey and the right choice of quality equipment. We’re about making the right tools that empower you to build your ideal lifestyle and fitness routine with confidence. ” explained RITFIT Founder Yann Lin, who come from a variety of backgrounds—from car design to IT engineering and furniture design. “But we’re all passionate about creating convenient, quality products for fitness at home. Starting in Delaware in 2015, we noticed a need for beginner-friendly, reasonably-priced equipment. So, we partnered with experienced fitness manufacturers to offer a product line that initially focused on yoga, Pilates, and dumbbells. With our commitment to quality and a drive for strength, we expanded into strength training gear, building a team that includes ex-athletes, nutritionists, ergonomic experts, and sports pedagogy professors. Many of us are also moms, dads, pet owners, and home gym users, so we understand the importance of safety and professionalism in our equipment.”

About RITFIT

RITFIT was born from a belief in the right to control one’s fitness journey and make the right choice in quality equipment. Founded in Delaware in 2015, the brand has grown from offering beginner-friendly yoga and Pilates gear to becoming an innovative force in strength training. With a team that includes ex-athletes, ergonomic experts, and dedicated home gym users, RITFIT holds over 60patents and is trusted by more than 300,000 customers to make home fitness simple, strong, and effective.

For more information, please follow RITFIT on Facebook (https://www.facebook.com/profile.php?id=61586121628607), Instagram (https://www.instagram.com/ritfit.de/) and Office Website(https://ritfitness.de/)

HONG KONG, March 24, 2026 /PRNewswire/ — InCorp Hong Kong, An Ascentium Company today announced its plan to planned rebranding to Ascentium, a leading global business services platform headquartered in Singapore. The move reflects the firm’s alignment with the broader Ascentium group and its long–standing commitment to supporting businesses operating in and from Hong Kong.

The rebranding brings together InCorp Hong Kong’s established strengths in corporate, accounting, tax, and compliance services with Ascentium’s international network of more than 2,600 professionals across 46 cities in 23 markets. Clients will continue to be supported by the same Hong Kong team, bolstered by enhanced resources, broader cross–border capabilities, and expanded access to HR, fiduciary, fund, and private client services.

The rebrand also underscores Ascentium’s view of Hong Kong as a critical hub for regional and global business activity. As regulatory and governance requirements become more interconnected, integrated cross-market support has become indispensable.

Conbie Siu, CEO of Ascentium Hong Kong, said: “Hong Kong has always been a place where local insight and international reach need to work hand in hand. Rebranding to Ascentium amplifies our ability to do exactly that, combining deep local understanding with the group’s global resources so we can support clients even more fully as they grow. Our clients trust us because we understand their business and stay with them through every stage of growth, and with global backing, we can continue those relationships while helping them scale and reach new heights.”

The rebranding will be introduced in phases ahead of the official launch in mid-May. All existing services, teams, and points of contact remain unchanged. Further updates will be shared as the rollout progresses.

About InCorp Hong Kong, An Ascentium Company

InCorp Hong Kong, An Ascentium Company is a trusted corporate services provider empowering entrepreneurs, SMEs, and multinationals to navigate Hong Kong’s dynamic business landscape with confidence. As part of the InCorp Global group, we offer a comprehensive suite of professional solutions, including company incorporation, corporate secretarial services, accounting, taxation, and regulatory compliance.

To learn more, visit hongkong.incorp.asia

About Ascentium

Ascentium is a leading global business services platform dedicated to helping businesses and individuals scale greater heights. Headquartered in Singapore, we drive extraordinary growth through expert people, purpose-led technology, and an unwavering commitment to service excellence.

With over 2,600 professionals across 46 cities in 23 markets globally, we deliver integrated solutions in corporate services, finance and accounting, fund administration, human resources, and fiduciary and trust services. Serving more than 63,000 client entities across diverse industries, Ascentium combines specialised expertise with innovative, technology-enabled solutions to help clients navigate complexity and unlock new opportunities for sustainable growth.

For more information, visit: ascentium.com